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Abstract: The inability to diagnose numerous diseases rapidly is a significant cause  
of the disparity of deaths resulting from both communicable and non-communicable 
diseases in the developing world in comparison to the developed world. Existing diagnostic 
instrumentation usually requires sophisticated infrastructure, stable electrical power, 
expensive reagents, long assay times, and highly trained personnel which is not often 
available in limited resource settings. This review will critically survey and analyse the 
current lateral flow-based point-of-care (POC) technologies, which have made a major 
impact on diagnostic testing in developing countries over the last 50 years. The future of 
POC technologies including the applications of microfluidics, which allows miniaturisation 
and integration of complex functions that facilitate their usage in limited resource settings, 
is discussed The advantages offered by such systems, including low cost, ruggedness and 
the capacity to generate accurate and reliable results rapidly, are well suited to the clinical 
and social settings of the developing world. 
Keywords: low-cost biosensors; point-of-care diagnostics; lateral flow immunoassay; 
microfluidics; global health 
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1. Introduction 
The long-term social and economic stability of a country is highly dependent on improved health. 
The worldwide advancement in health and technology in the last 50 years is far greater than in the 
previous 500 years [1]. In spite of technological advancements, developing countries still struggle with 
numerous health challenges. In addition to the non-communicable diseases common to all countries, 
such as obesity, diabetes, and cancer, developing countries still struggle with an additional disease 
burden from diseases which are preventable or treatable in the developed countries [2,3]. Though the 
burden of diseases is highest in the developing countries, laboratory or medical testing facilities are 
often limited and inaccessible to most patients, resulting in high mortality rates. The fundamental basis of 
evidence-based treatment is to find the cause of a patient’s illness. Reliable and accurate diagnostic 
investigations play a vital role in healthcare decisions, choice of treatment, and achievable survival. 
Although more than 50% of treatment decision-making is based on some diagnostics, it still accounts 
for less than 3% of the cost of healthcare. Unfortunately, a major aspect in developing countries is that 
they often lack modern laboratories, fully automated instruments that provide highly reproducible, 
quantitative, and hence sensitive and accurate diagnostic results. Rural areas often lack access to even 
basic diagnostic devices and trained personal. The scarcity of running water and reliable electrical 
services are additional challenges for delivering healthcare in these areas [4]. In order to circumvent 
these issues the emergence of rapid and easy-to-use point-of-care (POC) tests can dramatically 
enhance a physician’s ability to diagnose patients’ diseases rapidly and accurately. 
POC testing is a necessary component of affordable worldwide healthcare allowing rapid testing at, 
or near, the site of patient care. In limited-resource or non-existent healthcare settings, or where it is 
very hard to physically access relevant facilities, POC approaches can save hundreds of thousands of 
lives every year [5]. The global market for point-of-care diagnostics is expected to reach $27.5 billion 
by 2018 at an estimated compound annual growth rate (CAGR) of 9.3% from 2013–2018 [6]. The 
potential benefits of these rapid or POC diagnostics include the short turnaround time (TAT), minimal 
manual input, portability, low cost, immediate clinical decision-making, and “ease-of-use” formats so 
that they can be successfully deployed at the primary care level and are particularly amenable for use 
in remote settings with poor or no laboratory infrastructure [7]. In this paper, we review the diseases 
involved and the current healthcare challenges encountered by developing countries. We will discuss 
the present status of POC diagnostics in the developing world, highlighting, in particular, lateral flow 
technology-based devices. The latter platforms can make a major impact on diagnosis and treatment in 
limited-resource healthcare as they are low-cost, easy to transport, and use and generate results rapidly. 
Furthermore, we provide an overview on the latest advancements in the field of microfluidics-based 
devices, which allow miniaturisation of complex fluid handling steps, ease of multiplexing, and have 
integrated detection systems. 
Disease Burdens in the Developing World 
At present, the global population is more than 7 billion with a growth rate of around 1.14% per year, 
and it is expected to reach 9 billion or above by 2050. Developing countries account for 84% of the 
global population, with Asia accounting for approximately 60%, contributed to mainly by the two most 
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populous countries, China and India [8]. In spite of accounting for 90% of the global disease burden, 
the developing countries account for only 12% of global health expenditure [9]. The occurrence of 
both communicable and non-communicable diseases, such as diabetes, obesity, cardiovascular, and 
cancer, etc., is increasing at a much higher rate in developing countries than in the developed countries. 
Every year, acute respiratory infections account for approximately 4.3 million deaths, 1 million people 
die from malaria, and about 5 million from AIDS and tuberculosis in the developing world [10]. In 
2013, approximately 8 million people died with non-communicable diseases before their sixtieth 
birthday in these countries [11]. Developing countries are still struggling to meet the challenges of 
those diseases that are preventable or treatable in the developed world. 
Access to diagnostic tests and quality community screening can dramatically improve public health 
in the developing world. Accurate diagnosis plays a crucial role in identifying the incidence and root 
cause of diseases at both the individual and population levels. Most of the commercially available 
diagnostic tools for diseases are insufficient in meeting the needs of the limited-resource setting or a 
weak infrastructure-based healthcare set-up. These shortcomings include long TATs for testing  
with associated delay in availability of data resulting in late decision making. The development of  
point-of-care (POC) tests for limited-resource settings is an active and promising area for improving 
disease management. In addition to the increase in private-sector investment in diagnostics development, 
a number of initiatives funded by the public sector, including the European Union’s Seventh 
Framework Programme (FP7) and Horizon 2020, the UK’s Department for International Development, 
the Foundation for Innovative New Diagnostics, the U.S. Global Health Initiative, and the Bill & 
Melinda Gates Foundation are currently running with the objective to develop new diagnostic tools to 
support the healthcare systems of the developing world. An ideal diagnostic test for a limited-resource 
setting should have the following characteristics: be user friendly; generate results rapidly, allowing 
medical personnel to diagnose disease and start immediate treatment; be robust (no requirement for 
refrigerated storage); avoid requirements for complex pre-processing of biological samples; be portable, 
inexpensive, and highly sensitive; and have the requisite specificity [12]. Lateral flow devices are 
among the most established point-of-care testing platforms that have been successfully applied in areas 
where timely medical care is a challenge and they have most of the requisite characteristics previously 
described [13]. Numerous lateral flow test strips have been developed for diagnosis of infectious 
diseases as well as a range of disease-associated biomarkers, e.g., in cardiac disease and cancer. 
2. Lateral Flow Tests 
Lateral flow or Lateral Flow Immunoassay (LFIA) technology is the most simple and successful 
rapid diagnostic testing platform derived from the latex agglutination test developed by Singer and 
Plotz in 1956 [14]. Since its introduction, the technology and its applications in various fields, has 
continued to evolve. Its remarkable global growth can be attributed to numerous factors including the 
need for early stage detection of diseases like cancer, continuous demand for screening tools for 
preventive management of infectious diseases, and the requirement for cost-effective devices with little 
or no maintenance requirements. 
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2.1. Impact on Developing Countries 
The human pregnancy test was the key application driving the initial development of a rapid test 
platform; this made great strides in the 1970s in decentralized testing. Initially, the rapid tests for 
infectious diseases, including tests for human immunodeficiency virus (HIV-1 and HIV-2), TB, and 
hepatitis B were introduced in a dipstick format in developing countries. In the late 1980s, the first 
immunochromatographic strip (ICS) lateral flow format was introduced for disease diagnosis. Since 
then the technology, its applications, and the associated industry have continued to evolve. These test 
platforms have attractive performance features for developing countries, including stability for more 
than one year, precise performance, interpretation by minimally trained users, usability with a wide 
range of specimens, and no refrigeration required during shipping and storage. There are several 
thousand untrained persons performing rapid testing in developing countries [15]. Globally, more than 
100 companies are producing a wide range of lateral flow tests. Table 1 shows some of the commercially 
available LFIA strips and their performances. The data is divided into three different categories: 
infectious diseases, cancer, and cardiac diseases. In 2010 the US market accounted for US$1,680 million 
(50%), the European market around 40% (US$1,344 million), and the rest of the world accounted for 
10% (US$336 million) of the total rapid test market [16]. 
The development of LFIA tests for use in developing countries has focused mainly on infectious 
diseases, including HIV, Strep A/B, legionella, malaria, respiratory viruses, influenza, meningitis, 
filariasis, tuberculosis, measles, mumps, rubella, chlamydia, and gonorrhea [17]. The market leader for 
these tests, Alere, covered approximately 35% of the market. Various studies have shown that early 
diagnosis using LFIA platforms has benefits in disease prevention and treatment and also lowers the 
risk of transmission. LFIA for HIV testing has expanded rapidly worldwide [18]. The World Health 
Organization (WHO)/UNAIDS estimates that more than 5 million people received antiretroviral 
therapy, and more than 29 million people were tested for HIV infection in developing countries in 
2010 [19]. The HIV LFIA testing has also resulted in increasing the proportion of pregnant women 
who received their test result within a specified timeline and initiated antiretroviral therapy. The  
Ora Quick Rapid HIV-1/2 Antibody Test is a quantitative test for rapid HIV monitoring based on 
lateral flow technology for oral fluid specimens even at low concentrations of HIV antigens in oral 
fluid. The additional LFIA-based testing studies includes C-reactive protein determination among 
neonates suspected of having meningitis in South Africa, a tetanus immunity test in Iran, a test  
for trypanosomiasis in Angola, and a test for visceral leishmaniasis in Brazil, India, Kenya, and  
Sudan [12]. An early diagnosis using LFIA-based tests for pulmonary tuberculosis has also reduced 
mortality and transmission in low-resource settings. Cryptococcal antigen and Plasmodium falciparum 
malaria testing based on LFIA has also shown promising sensitivity for detection of disease and has 
benefited the developing countries in terms of reduced mortality [20,21]. 
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Table 1. Overview of commercially available lateral flow test strips: For detection of infectious diseases, cancer, and cardiac diseases. 
 Company Product Name Disease Analyte/Antigen (Ag) 
Required  
Sample 
Detection 
Time (Min) 
Sensitivity Specificity 
Infectious 
Diseases 
Alere Binax NOW Filariasis Lymphatic filariasis Wuchereria bancrofti 100 µL WB/S/P 10 - - 
IMMY CrAg A 
Cryptococcal 
meningitis 
C. neoformans C. gattii 40 µL of S/CSF 10 100% 94% 
Alere Binax NOW Malaria Plasmodium Ag 15 µL of WB 15 
P. falciparum: 
99.7%,  
P. vivax: 93.5% 
P. falciparum: 
94.2%,  
P. vivax: 99.8% 
Quidel Corp. Quick Vue RSV Test Infantile bronchiolitis 
Respiratory syncytial 
virus (RSV) Ag 
Nasal swab, 
aspirate and 
wash 
15 
92%-swab; 
99%-aspirate; 
83%-wash 
92%-swab; 
92%-aspirate; 
90%-wash 
Alere 
Alere Determine HIV-
1/2 Ag/Ab Combo 
AIDS 
HIV-1/2 antibodies and 
free HIV-1 p24 Ag 
50 µL of 
WB/S/P 
20 - 99.75% 
Alere 
Panbio Dengue Duo 
Cassette 
Dengue fever IgM and elevated IgG WB/S/P 15 85.50% 91.60% 
Alere 
Alere™ Influenza A & 
B Test 
Influenza 
Influenza A and B 
nucleoprotein Ag 
Nasal swab 10 
Flu A 93.8%; 
Flu B 77.4% 
Flu A 95.8%; 
Flu B 98% 
Alere 
Alere Determine TB 
LAM 
Tuberculosis (TB) in 
HIV positive patients 
Lipoarabinomannan 
(LAM) Ag 
60 µL of Urine 25 
51.7% for <100 
CD4 cell count 
>98% 
Trinity Biotech 
Uni-Gold™ Legionella 
Urinary Antigen PLUS 
Legionnaire’s 
Disease 
Legionella 
pneumophila serogroup 
1 Ag 
150–200 µL of 
Urine 
15 82.1% 99.2% 
Alere Binax NOW Pneumonia S. pneumoniae Ag Urine/CSF 15 
Urine-86%, 
CSF-97% 
Urine-94%, 
CSF-99% 
Cancer 
CTK Biotech 
On Site PSA Rapid 
Test 
Prostate cancer 
Prostate specific 
antigen (PSA) 
60–90 µL of S/P 10 Relative: 100% Relative: 99% 
Alere 
Alere NMP22 
BladderChek 
Bladder cancer 
Nuclear matrix protein 
(NMP22) 
4 drops of Urine 30 
99% when 
combined with 
cystoscopy 
99% NPV along 
with cystoscopy 
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Table 1. Cont. 
 Company Product Name Disease Analyte/Antigen (Ag) 
Required  
Sample 
Detection 
Time (Min) 
Sensitivity Specificity 
 
Alere Clearview iFOBT Colon cancer Faecal Occult Blood Faeces 5 93.60% 99.10% 
Arbor Vita 
Corp. 
OncoE6 Cervical Test Cervical cancer E6 oncoproteins Cervical swab 150 84.6% 98.5% 
Quicking 
Biotech Co., Ltd 
CA125 rapid test kit Ovarian Cancer CA125 Ag 100 µL of S 10 - - 
Innovation 
Biotech 
AFP Test 
Hepatocellular 
Cancer 
Alpha fetoprotein Ag S/P 10 25 ng/mL 99% 
Cardiac 
Diseases 
LifeSign 
StatusFirst CHF NT-
proBNP 
Congestive Heart 
Failure 
NT-proBNP 3 drops of P 15 20 pg/mL - 
BTNX Inc. 
Rapid Response CK-
MB Test 
Myocardial infarction 
(MI) 
Creatine kinase MB 
(CKMB) 
WB/S/P 10 5 ng/mL 99.80% 
Boditech Med 
Inc. 
ichroma™ CK-MB 
Test 
Myocardial infarction 
(MI) 
Creatine kinase MB 
(CKMB) 
75 µL of 
WB/S/P 
12 3 ng/mL - 
Response 
Biomedical 
Corp. 
RAMP MYOGLOBIN 
TEST 
Acute myocardial 
infarction (AMI) 
Myoglobin WB 10 2.36 ng/mL - 
Trinity Biotech Meritas® Troponin I 
Myocardial infarction 
(MI) 
Troponin I 200 µL of WB/P 15 0.036 ng/mL - 
BTNX Inc. 
RAPID RESPONSE 
D-DIMER TEST 
Venous 
Thromboembolism 
(VTE) 
D-Dimer WB/P 10 500 ng/mL - 
American 
Screening Corp. 
Instant-View Troponin 
I 
Acute myocardial 
infarction (AMI) 
Troponin I 200 µL of WB/S 10–20 - - 
WB-Whole blood, S-Serum, P-Plasma, CSF-Cerebrospinal fluid. 
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LFIA platforms have also impacted the cardiac disease diagnosis segment. The rapid results using 
LFIA platforms in cardiac ischaemia have resulted in the rapid diagnosis and precise medical treatment 
given at right time ensuring reinstatement of the blood flow to the heart. Using LFIA-combined with 
cardiac markers (CK-MB, myoglobin and troponin I/T, D-Dimer, hsCRP, and BNP (B-type natriuretic 
peptide)) has improved the early diagnosis of ischaemia resulting in better patient management [22].  
For example, in a study involving 817 patients enrolled in the ED for suspected AMI, the median time 
from sampling to reporting of results was 71.0 min for the central laboratory testing of CK-MB (by 
using Abbott’s AxSYM assays), whereas the POC testing of CK-MB, myoglobin, and cTnI using 
LFIA based test is 15–20 min [23]. The leader and innovator in the cardiac marker POC segment is 
Alere. There are many other companies that sell LFIA tests for all or one of these cardiac marker 
panels. These are listed in Table 1. 
2.2. Principle of a Lateral Flow Immunoassay 
Lateral flow immunoassay (LFIA) is based on the use of a nitrocellulose, polymer, paper, or other 
composite substrate membrane which facilitates the separation, capture, and detection of the target 
analyte(s) of interest. The various components of a LFIA have the capacity to transport fluid, including 
blood or serum, under capillary action, and thus no external pumps are required. 
There are various formats for lateral flow assays. In a simple capture format (Figure 1) the target 
analyte from the sample interacts with a labelled antibody, already pre-loaded on the strip, and 
migrates up the strip until it encounters another target-specific antibody, which is immobilised on the 
strip. The capture antibody-antigen-labelled antibody is then evident as a line which can be seen by eye 
or can be measured using a detector. A control is also present which uses a non-specific antibody and 
the presence of the associated line clearly demonstrates that the assay is working correctly. Other 
formats, e.g., competitive assays, are also possible, and may be particularly relevant where the target 
analyte does not possess multiple epitopes for antibody binding [17]. 
In practice, the system works as follows. Briefly, a sample is introduced on to the sample pad 
through the sample application window present on the plastic casing, as shown in Figure 2. The sample 
migrates through the sample pad to the conjugate pad, where the recognition element (antigen/antibody) 
is already available in a dried form. Here, the target analyte interacts with the dried labelled 
recognition element and the resulting complex further migrates to the next segment of the LFIA. This 
segment, the reaction matrix, consists of a hydrophobic nitrocellulose or cellulose acetate membrane 
where anti-target antibodies or antigen have been immobilised (depending on the type of format) in a 
line or band format across the membrane to act as a capture zone for capturing the labelled conjugate. 
This is followed by the presence of another zone, the control zone, which checks for assay 
functionality. Superfluous reagents, buffers, and assay fluids further migrate toward the absorbent pad 
and are absorbed as waste. The results are interpreted either by the naked eye or using a reader which 
evaluates the presence or absence of a test line along with the control line [24]. Figure 1 shows a 
schematic representation of the principle of a sandwich format lateral flow immunoassay. LFIA-based 
strips have different detection formats: sandwich and competitive. Figure 2 outlines key stages 
involved in a manufacturing process for lateral flow test strips. 
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Figure 1. Schematic representation of the principle of sandwich format of a lateral flow 
immunoassay. (A) Labelled lateral flow test strip; (B) Migration of sample from sample 
pad to conjugate pad; if the desired antigen is present in the sample the conjugate will bind 
to it creating a complex (antigen-antibody-label); (C) The complex flows through the 
membrane towards the test line; (D) Immobilised Ab captures the complex and free 
labelled Ab and forms test and control lines, respectively; (E) Qualitative results-visual 
detection; (F) Quantitative detection, e.g., optical detection (depending on label used). 
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Figure 2. (A) Outline of manufacturing process for lateral flow tests; (B) Top view of a 
lateral flow immunoassay test cartridge. 
The different constituents of a lateral flow test and the raw materials used for each constituent that 
play a vital role in the quality of the results generated are critically assessed in the next sections. 
2.2.1. Biorecognition Components 
The high specificity and selectivity of the biorecognition element are key for the performance of the 
assay. There are many different recognition elements that can be employed but antibodies are by far 
the most common and well established. Antibodies used in LFIA can be monoclonal, polyclonal, or 
both together, but increasingly recombinant antibodies are also being used. Traditionally polyclonal 
and monoclonal antibodies have been used extensively. Both have their own advantages, including the 
high specificity of monoclonal antibodies, which helps in decreasing non-specificity and cross-reactivity, 
while the ability of polyclonal antibodies to recognize multiple epitopes on a single antigen, as well as 
their low cost production in bulk quantities, are valuable properties. Many rapid tests employ 2–3 types 
of antibodies, e.g., for binding specifically to the target antigen, for carrying the label for visualisation, 
and for acting as a control. The stationary phase includes antibodies immobilised at the capture line 
location (specific to target analyte) to capture antigen, and another at the control line. The mobile 
phase contains the antibody bound with a label, e.g., enzymes, fluorescent tags, gold nanoparticles, 
quantum dots, or latex beads, which first interact with the target analyte in a direct or sandwich 
immunoassay format and then come in contact with the immobilised capture antibodies. Recently, the 
potential of using recombinant antibodies is being explored. This derives from the fact that their 
specificity can be carefully tuned to allow either broad or highly specific binding, allowing the analysis 
of groups of related targets or analysis of an individual target. They can also be functionalised to allow 
high levels of immobilisation with optimal orientation. In addition, the labels may be molecularly 
linked to the antibody, e.g., use of green or other fluorescent proteins, thus avoiding labelling steps 
which may lead to conjugations that may reduce or even inhibit the antigen- binding capacity of some 
antibody molecules. Issues related to stability may be overcome by additional engineering to create 
formats e.g., Fabs or scAbs, that work well in LFIA. In addition to antibodies, aptamers, affimers, 
Biosensors 2015, 5 586 
 
 
more complex molecularly imprinted polymers, and several other binders are being explored as 
promising alternative capture probes [25–27]. There are three types of aptamers: DNA, RNA, and 
peptide aptamers. Single-stranded DNA or RNA (ssDNA or ssRNA) molecules can bind to selected 
targets, including proteins and peptides, with high affinity and specificity. Organic molecules having 
molecular weights in the range of 100–10,000 Da are ideal targets for aptamers. 
2.2.2. Sample Application Pad 
Cellulose, glass fibre, rayon, or cross-linked silica are common materials used to make sample 
application pads. The major role of the sample pad is to allow continuously uniform migration of the 
sample to the conjugate pad whilst making the sample compatible with the other components of the 
test system. This is usually achieved by pre-treatment of the sample by separating the plasma or serum 
from whole blood and may involve trapping of erythrocytes and other cells, adjustment of pH, and 
elimination of interferents, in order to allow efficient interaction of the target analyte with antibodies 
and conjugates. 
2.2.3. Conjugate Pad 
The sample migrates from the sample pad to the conjugate pad where it mixes with the dried 
conjugates (e.g., antibodies specific to target analyte tagged with a label). Conjugate pads are usually 
made up of glass fibres or polyesters and are often pre-treated with different proteins, polymers, and 
surfactants to make them hydrophilic in order to ensure stability and optimum release of the conjugate. 
The material composing a conjugate pad often plays a vital role in determining the overall shelf-life  
of the LFIA test by ensuring the stability of antibodies, labels, and the associated conjugates, and 
allowing release of the conjugates from the pad [17]. During manufacture, the conjugates are 
dispensed on the pad using a quantitative dispenser such as the BioDot AirJet Quanti 3000 in order to 
maintain the uniform dispensing and, thus, the reproducibility of the components. High levels of 
control and precise dispensing of reagents are vital for good performance. Variations in conjugate 
mixing, deposition, or release from the pad result in significant deviations in assay performance. 
2.2.4. Membrane 
A wide variety of membrane types and pore sizes are commercially available. The selection of the 
membrane depends on the analyte and the application of the test. Typically, a hydrophobic 
nitrocellulose (high protein binding), glass fibre (non-protein binding), or cellulose acetate (low 
protein binding) membranes are used for LFIA. Nitrocellulose membranes are the most widely 
accepted materials that have been efficaciously applied for LFIA tests due to their distinctive 
characteristics including high affinity for proteins, ease of wetting, lack of interference with assay, 
relatively low cost, commercial availability of several versions of nitrocellulose, true capillary flow 
characteristics, and comparative ease of handling. The reaction area is comprised of two lines or zones 
on the nitrocellulose membrane, known as the test (or capture) and control lines. The capture line 
consists of specific antigen or antibodies immobilised to capture the target analyte whereas the 
presence of the control line confirms the proper flow of the liquid or performance of the assay. Several 
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factors including accurate dispensing of biological components and proper blocking and drying play a 
key role in refining sensitivity of the assay. 
2.2.5. Absorbent Pad 
The absorbent pad is usually made up of high-density cellulose and is placed at the end of the strip 
or after reaction region. The main role of an absorbent pad is to maintain the flow of reagents over the 
membrane and to avoid false positives by not allowing back flow of reagents. It is also called a wick or 
the sink in an LFIA system. 
2.2.6. Backing Materials for the Membrane 
In order to facilitate easy handling and to provide strength to the fragile membranes used in the 
LFIA system, all capillary beds are usually mounted on a backing material. The materials used for 
providing the requisite rigidity are typically polystyrene or different variants of plastic which are 
coated with a pressure-sensitive adhesive to hold all the components together in a defined format. The 
compatibility of proteins with adhesives over a long period of time plays an important role in 
maintaining the prescribed shelf-life of the product. The backing serves as a structural support to the 
LFIA system to which several layers (e.g., pads) performing different functions are laminated and the 
entire entity is housed in a single cassette. 
2.2.7. Detection Label 
The choice of a label used for detection normally depends on the application of the LFIA system. 
Labels such as latex beads, colloidal carbon, colloidal gold, fluorescent tags, enzymes, streptavidin, or 
gold nanoparticles, are conjugated with an antibody or an antigen depending on the format of the LFIA 
system [28–30]. Several forms of latex beads coupled with coloured dyes, fluorescent dyes, or 
magnetic elements are commercially available and can be attached covalently or electrostatically with 
the proteins. The presence of coloured labels avoids the requirement for costly detectors and allows the 
visual detection of the target analyte. The capacity for coupling latex beads with different colours can 
allow multiple analyte detection on a single test membrane. Evolution of nanomaterials has improved 
the sensitivity of these assays tremendously. The inherent properties of gold nanoparticles, including 
strong optical properties (intense colour), and the smaller size of gold particles (20–40 nm) in 
comparison to latex beads (100–300 nm) make them good candidates for enhancing sensitivity and, 
thus, for application in LFIA systems. The colour intensity of gold nanoparticles is much higher than 
coloured latex particles, thus providing better discrimination of low level positives in an assay. Several 
other nanomaterials, including silver ions on gold nanoparticles, have been integrated into LFIAs to 
further enhance the sensitivity of the system. In the ideal situation, the assay may be able to detect 
multiple analytes. This can be achieved by running multiple lanes on the one strip in parallel with 
individual detection sites. Alternatively, barcoding is possible with different labels demonstrating  
the presence of different analytes. Many different formats are possible but in resource-limited 
environments simplicity in use, sensitivity, and specificity are key. 
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2.2.8. Detection System 
The majority of the lateral flow assays use visual detection. The incorporation of gold nanoparticles 
or latex beads as labels allows visual examination of colours at the test and control lines, resulting in 
qualitative or semi-quantitative analysis. The generation of rapid results in critical or intensive care 
unit (ICU) patients is of great assistance to doctors to make an instantaneous decision and initiate 
treatment. The use of colloidal gold, paramagnetic particles, and fluorescent dyes as labels in lateral 
flow formats has opened up new horizons for LFIA technology by allowing true quantitative testing. 
The development of quantitative assays in lateral flow formats requires an additional fluorescence or 
optical strip reader which allows measurement of the intensity produced at the test and control lines of 
the strip [31–33]. The readers are based on the use of different wavelengths of light for illumination, in 
combination with a camera or charge-coupled device (CCD) imaging technology which allows capture 
of images of test and control lines. Furthermore, an integrated image processing algorithm converts the 
intensity of the lines to the corresponding analyte concentration. The selection of detector is chiefly 
determined by the detection label used in analysis. Fluorescent or paramagnetic particles allow the 
achievement of 1–2 orders of magnitude of higher sensitivity in comparison to visual labels, such as 
colloidal gold or coloured latex. The precise positioning of the test and control lines on the strip and 
background correction is of crucial importance for optimal performance in these systems. More 
recently the use of mobile phone-based detection strategies is being explored and this may well 
provide a valuable strategy for use in “resource-poor” environments. 
2.3. Limitations of “Traditional” POC Approaches 
As discussed above, LFIA techniques have allowed quick and simple point-of-care diagnosis of a 
variety of diseases in different environments. However, their simplicity limits their performance and in 
many cases more complex devices are necessary for accurate diagnosis. LFIA or immunochromatographic 
(ICS)-based strips have successfully been implemented for the diagnosis of several transferable 
diseases such as HIV, tuberculosis, and sexually-transmitted diseases (STDs) in low-resource settings. 
ICS strips rely on capillary forces to control fluid flow. By the nature of sample addition to  
such devices, there may be some variations in the amount of sample added initially and actually  
used in the test and this can result in poor precision. In addition, in many test formats pre-treatment  
of samples becomes mandatory in cases where the sample matrix is not a fluid or where  
significant interferents are present. In addition to this, restrictions in the limit of detection of these 
platforms may restrict their use to the determination of analytes that are highly abundant in the sample 
tested, such as lymphocytes in HIV tests or pathogenic microorganisms in malaria tests. Hence, the 
results may be only qualitative or semi-quantitative, even when confirmed with a reader. The large 
coefficient of variation (CV) associated with an LFIA test also limits the test reproducibility and, 
therefore, its ability to confirm the presence of the disease [17]. Variable test performance due to 
variations in environmental factors such as temperature, humidity, heat, air, and sunlight are added 
complications [34]. 
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3. The Future: Microfluidics as an Emerging Platform for Point-of-Care Diagnosis 
Over the last two decades, microfluidic technologies have experienced a significant growth in 
applications in the field of diagnosis. Microfluidics-based instrumentation has shown promising results 
in several of the main laboratory techniques, including blood chemistries, immunoassays, nucleic-acid 
amplification tests, and flow cytometry [35]. Microfluidics allows the miniaturisation and automation 
of diagnostic devices and has been touted as capable of supplanting (or at least complementing) LFIA 
devices for health care applications in POC settings. It presents several advantages compared with 
LFIA technologies. These include the ability for extensive use of complex multiplexing approaches 
and formats, the capacity for inclusion of sequential sample pre-conditioning steps of different types, 
reagent storage, the use of multiple steps involving reagent addition, mixing and washing, the potential 
for incorporation of centrifugal steps at various speeds, and the application of a range of detection 
strategies leading to greater sensitivity and clarity of results. 
3.1. Microfluidic Devices in Developing Countries 
Fully automated instruments located in centralised laboratories are capable of providing highly 
reproducible, quantitative, and sensitive results. Unfortunately, in developing countries, the necessary 
infrastructure for these modern laboratories, if available, is often only present in the major cities’ 
hospitals or in regional centres. Rural areas often lack access to the requisite technology and the 
necessary trained personal to perform the tests and carry out the subsequent diagnoses, especially 
where the situation is complicated for patients with multiple concomitant infections and malnutrition. 
When developing a diagnostic device intended for use in resource-poor areas, it is of utmost 
importance to ensure it conforms to the stringent performance requirements previously listed in earlier 
sections of this review. Microfluidic-based systems are able to fulfil these requirements by 
miniaturising and automating complex diagnostic procedures into a portable device [35]. 
Several academic and industrial groups have explored the potential of microfluidic-based 
technologies to be used in resource-poor settings in developing countries. Patterned-paper technology 
(Figure 3) is being widely evaluated since the Diagnostics for All’s (DFA) mission was founded in 
2007 by George Whitesides and his group in Harvard University aiming to improve diagnostics 
approaches in developing countries. DFA is working on the development of low-cost, easy-to-use POC 
tests that require no power or trained clinicians [36]. Whitesides’s group demonstrated the potential of 
a patterned paper device for monitoring drug-induced hepatoxicity in at-risk individuals, such as those 
being treated for tuberculosis and/or HIV. The test linearity showed that aspartate aminotransferase 
and alanine aminotransferase (indicators of liver function) assays were linear across the clinical range 
(40–200 U/L), and CV values were <10% for both tests [37]. Other microfluidic platforms such as  
lab-on-a-disc and lab-on-a-chip devices are being presented as attractive solutions for POC settings 
(Figure 3). Hugo et al. [38] analysed the implementation of a centrifugal microfluidic platform for 
POC applications in South Africa. The results of the microfluidic disc example showed how functions 
such as valving, mixing, pumping, and separation of fluids can be integrated into the centrifugal 
microfluidic platform for diagnostic applications. Work has also begun on the development of a  
lab-on-a-chip for malaria diagnosis consisting of a disposable disc and a portable RT-PCR machine.  
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A third party evaluation of the prototype device yielded a sensitivity of 96.7% and a specificity of 100% 
(n = 38) [39]. The use of a microfluidic platform for diagnostic of the Mycobacterium tuberculosis has 
also been reported. Jing et al. [40] integrated an on-chip airborne bacteria capture system and a rapid 
bacteriological immunoassay into an automated microfluidic system that was able to detect the 
pathogen in 50 min, eliminating the need of a culturing step. Other researchers have introduced a magnetic 
nanoparticle/quantum dot-based immunoassay for the detection of pathogens responsible for 
waterborne and foodborne diseases (e.g., E. coli 0157:H7, Salmonella, etc.) using a microfluidic chip. 
The chip consists of two microchannels embedded with magnets, where immunomagnetic separation 
of the bacteria takes place. Detection is achieved by labelling the captured bacteria with bioconjugated 
quantum dots which fluorescence [41]. To date, however, these microfluidic devices are still not 
suitable to use in the developing world, and most of them remain in a proof-of-concept state, lacking 
the clinical trials needed to clear the test. Some companies have, nevertheless, managed to satisfy all 
the criteria needed to launch their POC tests on the market. Table 2, adapted from Chin et al. [7], 
shows a compilation of the FDA-approved microfluidics-based technologies for “on-site” tests. 
 
Figure 3. Examples of microfluidic-based platforms. (A) Paper-based microfluidic device 
for simultaneous quantification of glucose and other analyte in urine. Taken from 
http://gmwgroup.harvard.edu with permission from Prof. Whitesides; (B) Lab-on-a-chip 
platform developed by Alere for blood chemistry analysis. Reproduced with permission 
from Alere; (C) Lab-on-a-disc diagnostic device designed by Abaxis. Reproduced with 
permission from Abaxis. 
A. 
B. 
C. 
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Table 2. List of FDA-approved microfluidic-based POC tests. Adapted from Chin et al. [7]. 
Company Test Name 
Tested 
Analyte/Parameter 
Sample Required Components 
Training Requirements and 
Other Characteristics 
Results Type and 
Turnaround Time 
Abaxis The Piccolo® Blood chemistries 
100 µL of WB, S 
or P 
Disposable test discs and 
portable analyser. 
No operator intervention is 
required. 
Quantitative results in 
about 12 min. 
Biosite (Alere) 
Alere Triage® 
MeterPro 
Blood/urine chemistries 
including “waived” Lipid 
and liver panels 
225 µL of WB, P 
or urine 
Disposable cartridges, and 
meter. 
No training required. Built-in 
quality controls. 
Qualitative results in 
15–20 min. 
Epocal (Alere) 
The epoc® Blood 
Analysis System 
Blood chemistries 92 μL of WB 
Test cards and wireless 
card reader with a host 
mobile computer. 
No training required. RT- test 
card storage. Automated, 
built-in QC/QA calibration 
and quality tests 
Quantitative results in 
about 30 s. 
Focus Dx 
(Quest) 
Simplexa Flu A/B & RSV 
Nasopharyngeal 
swabs 
PCR platform (3M™ 
Integrated Cycler) and 
amplification discs with 
sample wells. 
Used by physician. 
Quantitative results in 
1 h. 
HandlyLab 
(BD) 
BD MAXTM 
GBS Assay IDI-
Strep B Assay 
Group B Streptococcus 
(GBS) 
Vaginal/rectal 
swab samples 
Cepheid Smart Cycler® 
RT-PCR system, 
disposable cartridge and 
computer system. 
Trained personal required. 
Can be performed in moderate 
complexity laboratories. 
Qualitative results in 
1 h. 
i-STAT Corp 
(Abbot) 
i-STAT Analyser 
Blood chemistries; 
coagulation; cardiac 
markers 
17–95 μL of WB, 
depending on 
cartridge type 
Handheld analyser and 
self-contained cartridges. 
Training is required. Portable. 
Cartridges can be stored at 
room temperature. 
Quantitative results in 
less than 15 min. 
Idaho 
Technologies 
FilmArray RP 
Panel of respiratory 
pathogens 
Nasopharyngeal 
swabs 
FilmArray instrument and 
freeze-dried reagents in 
pouches 
No precise measuring or 
pipetting required. 
Qualitative results.  
2 min. of hands-on 
time; about a 1-h 
turnaround time. 
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Table 2. Cont. 
Company Test Name 
Tested 
Analyte/Parameter 
Sample Required Components 
Training Requirements and 
Other Characteristics 
Results Type and 
Turnaround Time 
IQuum 
Liat™ Influenza 
A/B Assay 
H1N1 influenza viral 
RNA 
Nasopharyngeal 
swab samples 
Benchtop analyzer 
disposable assay tubes 
Use under CLIA 
requirements. Can be operated 
by minimally trained users. 
Qualitative results in 
less than 30 min. 
Micronics 
(Sony) 
ABORhCard 
ABO and Rh blood 
typing 
50 μL of 
fingerstick WB  
Disposable cards that with 
anti-A, B and D antibodies 
printed into discrete 
microfluidic channels. 
No training required. No 
refrigeration needed. Long 
shelf-life. 
Qualitative results in 
approximately 2 min. 
Sphere Medical Proxima Blood chemistry Arterial WB 
Disposable multi-
parameter microanalyser, 
silicon chips. 
Use by trained clinician. 
Quantitative results in 
approximately 3 min. 
TearLab 
TearLab 
Osmolarity 
System 
Osmolarity of human 
tears (diagnosis of Dry 
Eye Disease) 
50 nL of tear film 
Disposable microchip 
works in conjunction with 
a pen that convey data to 
the osmolarity reader. 
Professional in vitro 
diagnostic use only. 
Quantitative results in 
seconds. 
WB-Whole blood, S-Serum, P-Plasma. 
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The Alere epoc® blood analysis system (see Figure 3) is a POC platform for blood gas, electrolyte, 
and metabolite testing. This system integrates a variety of assays that run simultaneously in a 
disposable and low-cost card, producing reliable results determined on a reusable wireless reader. 
Alere developed the Pima CD4 test (CE marked), consisting of disposable cartridges and a benchtop 
cytometer. In this test, the dried reagents are sealed in the cartridge, which does not require 
refrigeration, and the analyser can work with either battery or mains A/C power. Fluorescently-labelled 
anti-CD3 and anti-CD4 antibodies are incubated with the sample, which once stained, is transferred to 
a detection channel where the signal is measured by the analyser. With a cost of $8.70 per test, this 
technology was designed for low-resource settings [42,43]. They also developed a system, called Alere 
Connectivity solution, to connect Pima analysers located in isolated areas to a centralised data 
warehouse, bringing the availability of high quality lab services to rural areas in developing countries. 
FDA-approved lab-on-a-disc platform Piccolo analysers introduced by Abaxis (see Figure 3) consist of 
a disposable, self-contained plastic disc and an analyser. The blood sample is loaded onto the disc, 
which is then placed into the analyser tray. Using centrifugal and capillary forces, plasma separation, 
metering, dilution, mixing, and distribution to the cuvettes containing the lyophilised reagents take 
place in the disc. The Piccolo has been used by the French, British, and US Military in remote 
locations and has also proved to be an appropriate blood chemistry analyser for biosafety environments, 
such as those required for monitoring Ebola patients [44]. Claros Diagnostics (now part of OPKO 
Health) is another company that has focused its efforts on the development of POC diagnostic devices 
for developing countries. Their platform consists of a blood-collector device, a disposable cartridge, 
and a reader, and obtained the CE Mark for the detection of prostate cancer-associated prostate specific 
antigen. This assay is based on a sandwich assay in which a gold nanoparticle-conjugated antibody is 
used in the detection process. The reduction of silver ions on these gold nanoparticles yields an 
amplified signal that can be optically measured. OPKO also developed a test for the detection of a 
panel of sexual-transmitted diseases (HIV, syphilis, and hepatitis C) in collaboration with Samuel K. Sia 
(co-funder of Claros Diagnostics) of Columbia University. A smartphone dongle (microfluidic cassette) 
was used to run the assays, which showed a sensitivity of 92%–100% and specificity of 79%–100% in 
a field study in Rwanda [45]. Iquum has a FDA-approved test for Flu A/B and have also developed a 
HIV test using the same analyser. Liat’s HIV Quant whole-blood assay was evaluated in South Africa 
yielding a specificity of approximately 88%. Further development of this test is still required [46]. 
The implementation of new POC diagnostic tools must overcome regulatory challenges. Many 
emerging microfluidic POC technologies have significant but unproved potential to improve global 
health. Regulatory processes, despite being time-consuming, are essential to assure the effectiveness 
and reliability of diagnostic tests. In locations where laboratory equipment and trained personal are not 
available, the use of diagnostic devices is regulated by the requirements of the Clinical Laboratory 
Improvement Amendments of 1988 (CLIA) in addition to the traditional Premarket Approval (PMA) 
or the approval via the 510(k) pathway in the U.S.A. For diagnostic tests to be CLIA-waived they  
must be simple and have a minimum risk for generating erroneous results. This means that sample 
preparation and fluid handling steps must be minimised, ideally by storing reagents on the  
microfluidic device and automatically releasing them. Chin et al. [7] summarised the CLIA-waiver 
requirements that must be taken into account when designing a diagnostic device intended to be used 
in developing countries. These are: (1) it should be a self-contained and automated test, allowing the  
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use of unprocessed specimens; (2) it should not require technical training; (3) it should provide  
easily-interpreted results; and (4) it should be a robust test, able to handle variability in performing 
timings, storage conditions, etc. [7]. 
3.2. Self-Contained and Automated Testing 
It is a challenge to integrate sample preparation and processing and detection techniques in a  
self-contained POC system. Non-instrumental, disposable-only tests would be ideal for delivering  
health care in low-resources settings as they are cheap and simple to perform. Thus, “disposable-only” 
microfluidic devices are especially suited for developing country diagnostics. Currently, these  
non-instrument-based tests are found in three different formats: lateral flow, flow-through, or solid 
phase. Unfortunately, the limitations in the limit of detection inherent to these platforms makes those 
disposables with an external reader a better alternative in many cases, in particular when the tested 
analyte is not very abundant in the sample [47]. 
The integration of multiple preparative and analytical microfluidic technologies in a single device 
allows the use of unprocessed samples to run an entire assay at a POC setting. Preconditioning of 
samples, when needed, is possible thanks to centrifugation, which allows the purification of plasma 
from blood, or microfluidic technologies such as an on-chip filter trench where blood cells are 
sedimented and captured [35,48]. As mentioned previously, microfluidic systems facilitate the 
miniaturisation of assays, thus reducing the surface-to-volume ratios, enhancing aspects of assay kinetics 
and allowing significant reductions in sample/reagent volumes. In this context of micrometre-sized 
channels, sample flow is laminar, and fluid mixing needs to be achieved by means other than 
traditional turbulent diffusion. Controlled fluid flow and mixing is essential for biosensing and in a 
microfluidic system this can be accomplished by passive methods (e.g., by lamination, use of specific 
surface chemistries for immobilisation of reagents, minimisation of non-specific binding, generation of 
hydrophobic/hydrophilic regions, and by use of specific geometries or topographies of channels), by 
the use of micro-pumps or micro-valves, or by applying an external energy supply [49]. The ability of 
sacrificial valves to create vapour barriers makes them ideal for reagent storage. Traditionally, 
sacrificial valves required external actuators (e.g., laser diodes) in order to be activated. The use of all 
external actuators except spindle motor can be excluded by using new valve designs, such as 
dissolvable-film (DF) valves that dissolve beyond a critical rotational frequency [50]. Since passive 
methods do not require external sources of energy, they are the most suitable for use in those  
areas with limited technological resources. Suitable alternatives are the aforementioned centrifugal 
microfluidic platforms, which offer precise fluid control and only require a simple motor for powering 
the system [38]. The technology needed to drive the microfluidic discs is as simple as that used in CD 
players or DVD drivers. Glynn et al. [51] developed a microfluidic “lab-on-a-disc” device that was 
able to purify cells expressing the HIV/AIDS-relevant epitope, CD4, from whole blood using 
centrifuge-magnetophoresis for cell isolation. This proved to be a cheap, simple, and efficient method 
that could be exploited for on-site diagnosis. Such microfluidic platforms can perform relatively 
complex analytical tests, which make them highly suitable for healthcare applications in remote areas. 
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3.3. No Specialised Training Requirements 
Beyond the technical challenges, successful implementation of a diagnostic test in remote settings 
relies on the ability of the user to operate the test. The development of an appropriate interface is of 
utmost importance in those low-resource areas where healthcare workers are often not professional 
clinicians. These individuals would be able to perform basic tests, such as ICS strips for pregnancy or 
malaria, but may encounter difficulty if they need to prepare the samples or handle different  
reagents [35]. Microfluidic platforms overcome this problem by integrating sample preparation and all 
the immunoassay steps into a disposable self-integrated cartridge, which contains all the necessary 
reagents to run the test, allowing an automised analysis and minimising “hands-on” time. Once the 
sample is added to the cartridge, washing and calibration steps occur with no further liquid handling 
required. This reduces the exposure of the sample to the environment (avoiding contamination) and the 
operator-associated variability in the results. An example of a user-friendly test is the ABORhCard 
(from Sony) for the determination of the ABO group and Rh factor from a fingerstick blood sample. 
This device has been FDA-cleared and it is being used by the U.S. military in the Middle East, proving 
its suitability for austere environments. Anti-A, anti-B, and anti-D (Rh) antibodies are contained in 
channels in the card and re-hydrated by the addition of buffer prior to sample addition. The steps 
required to perform the test are summarised in Figure 4. 
 
 
Figure 4. ABORhCard summarised assay procedure. Buffer is manually added by the user 
to re-hydrate the antibodies and this process is confirmed by the visualisation of colours in 
the A, B, and D “verification windows”. Then, using the lancet provided, a fingerstick 
blood sample is collected and added into the “blood” well. Once the colour appears in the 
“verification window”, the blood and reagents mix and flow into the “results window”  
using the on-board Pump (P) and Vent (V). At the end of the procedure, agglutination  
occurs and results can be visualised. Images taken from www.micronics.net with 
permission from Micronics. 
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All of the steps involved in the diagnostic procedure should be simple and as culturally independent 
as possible. Reading a basic instruction manual written in non-technical language should enable the 
user to operate the test without any further “hands-on” training. The training requirements of a variety 
of FDA-approved microfluidics-based POC tests are shown in Table 2. 
3.4. Easily Interpreted Results 
A diagnostic test usually gives information regarding the presence/absence or concentration of the 
analyte of interest contained in a biological sample [47]. Healthcare workers in remote areas in 
developing countries may have little training, so it is desirable that the results are presented in a simple 
format to avoid misinterpretation. For example, Biosite (Alere) developed a system test with up to  
16 immunoassays that provides qualitative results displayed as positive (POS) or negative (NEG) that 
are easy to interpret. Another alternative is transmitting the results data to a central laboratory with a 
cell phone for telemedicine, so experts can do a real-time analysis of the results. This was the chosen 
approach by Martinez et al. [52], who described a system in which they combined an inexpensive  
paper-based microfluidics diagnostic platform with a camera phone to quantify the results and 
exchange the information with trained staff. Smartphones are available worldwide, even in remote 
areas, and telemedicine offers a useful starting point for diagnostic platforms in low-resource areas. 
One of the strengths of microfluidics is that they are able to produce sensitive results by detecting 
the signal produced in a very small area using fluorescence or other more recently implemented but 
ultrasensitive detection methods. Electrochemical detection, in particular, has been widely used for 
improving the sensitivity and also often the specificity of traditional tests, generating quantitative  
testing due to the use of portable electrochemical analysers in POC platforms. For example, the i-Stat 
blood gas analyser (see Table 2) combines self-contained cartridges with microfluidic components and 
electrochemical detection (including amperometry, voltammetry, and conductance, depending on the 
testing analyte). Each cartridge contains a sample chamber, a calibration solution, a waste chamber, 
and a unique combination of sensors, depending on the test. i-Stat analysers are battery-powered and 
have been used in some remote health centres in Australia [53], where, however, it is not yet part of 
the standard equipment provided. In developing countries, the main obstacle for the implementation  
of this test is the relatively high cost—an i-STAT analyser costs approximately $6000. Despite this,  
the price of each test (approximately $9) is still lower than performing the analysis in a central  
laboratory [54], and could be further reduced for implementation in developing countries. 
3.5. Necessity of a Robust Test 
For POC testing to reach its full potential in a low-resource setting, disposables need to be robust, 
allowing shipping and storage at ambient temperature. Reagents and antibodies for immunoassays 
must be stored on the disposable element. To avoid degradation, biomolecules would ideally be stored 
in a lyophilised state in vapour-proof compartments. This would protect their integrity, allowing them 
to be stored at ambient temperature and also would reduce the weight of disposables, which would 
contain only desiccated reagents. If the use of liquid reagents is necessary, they should be contained in 
a sterile and sealed environment to prevent evaporation [35]. Dry reagents enclosed in small cartridges 
or disposal discs that do not require to be refrigerated are best suited for resource-limited areas.  
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That is the case of the Pima CD4 test, Piccolo® reagent discs or the ABORhCard, already described in 
this review. 
To test the efficiency of the test, a calibration check should be run in parallel to the test, ideally 
including both positive and negative controls. Thus, a microfluidic platform in which both a standard 
curve and the analyte test can be simultaneously generated on the same disc or chip is particularly 
attractive [27]. 
3.6. General Observations 
Microfluidic technologies offer significant benefits for implementation in developing areas. 
Reducing the cost of materials to be used in the disposables is a must be taken into consideration.  
To minimise manufacturing costs, microfluidic devices can be made of plastic (produced by lamination, 
injection moulding, or embossing) or paper, both inexpensive materials appropriate for the fabrication 
of disposable devices [7]. In addition, lab-on-a-chip and lab-on-a-disc technologies have demonstrated 
their utility for use in remote areas, as they are compact, easy to use, and multifunctional. Individual 
components of microfluidic platforms, such as those needed for sample pre-treatment or reagent 
mixing have undergone significant improvements in recent years. Research efforts should now focus 
on the integration of all these components into a self-contained device. Only when this is achieved, and 
the systems become fully compliant with regulatory requirements, can such new clinically-relevant 
POC devices be brought to the market and their full potential exploited for improved global healthcare. 
4. Conclusions 
Developing countries have a much higher mortality rate from diseases such as HIV, TB, and 
malaria due to poor medical infrastructure in comparison to the developed countries. In addition to the 
communicable diseases, non-communicable diseases are also imposing a growing burden upon the 
resource-limited countries. The development of inexpensive, low-maintenance, reliable, and easy-to-use 
diagnostic tools can easily reduce the burden and impact of diseases in these environments. Despite the 
presence of high disease burdens and an ever-growing need, there are relatively few diagnostic tools 
that have been designed for fulfilling the specific needs and challenges of the developing countries. 
Currently, the only highly successful point-of-care (POC) testing platform available in the rural areas 
of developing countries is the lateral flow assay LFIA strip, which has contributed greatly to the 
identification of diseases without the requirement for any modern laboratory set-up. In spite of the 
advantages offered by LFIA strips, there are several inherent associated weaknesses, as indicated  
by clinicians and researchers, such as poor reproducibility and accuracy, and low sensitivity. 
Advancements in nanotechnology, microfluidics, and device fabrication have opened up new horizons 
in the field of diagnostic platforms for their successful placement in low-resource laboratory settings. 
Their intrinsic advantages, such as small size, manipulation of small volumes of liquids, high 
capability of integration, and rapid reactions offered by microfluidic technology make them promising 
candidates as POC diagnostic platforms. The ability of microfluidics based-platforms to accomplish all 
analytical steps such as sample pretreatment, assay, and detection, on a single easy-to-use, accurate 
and automatic test system makes them an ideal future diagnostic tool to provide real clinical value in 
low-resource, laboratory-free settings. 
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